Rocket Pharma Q2 net income $123.2M on PRV sale; cash $283.7M, runway to Q2 2028

ROCKET PHARMACEUTICALS, INC.

2026-Q2 EPS reported $0.66

Net income $123.2M ($1.09 basic EPS) vs net loss $68.9M ($0.62 loss) in Q2 2025.
Other income $178.8M includes $178.2M net from Rare Pediatric Disease PRV sale (closed June 12, 2026).
RP-A501: all 3 initial Danon disease patients completed safety observation; no TMA or capillary leak.
KRESLADI (LAD-I) FDA approved; commercial availability and patient onboarding expected Q4 2026.
Cash $283.7M at June 30, 2026; expected to fund operations into Q2 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.